Discussion on the Mechanism of Lithospermumerythrorhizon in the Treatment of Cervical Cancer Based on Network Pharmacology and Molecular Docking Technology

Abstract

Objective To explore the "multi-component, multi-target, multi-pathway" mechanism of Lithospermum erythrorhizonagainst cervical cancer.Methods The active ingredients and corresponding targets were screened through TCMSP, PubChem and SwissTargetPrediction databases. The GeneCarts platform was used to collect cervical cancer-related genes, and the intersection of drug targets and cervical cancer targets was analyzed. Use STRING to analyze protein interaction network, use Cytoscape software to construct component-target and core target interaction network, perform KEGG pathway enrichment analysis on core target genes, and conduct molecular docking verification.Results After screening, 12 main active ingredients of comfrey (including Shikonin A, 1-methoxyacetylshikonin, Shikonin B, etc.) and 35 key targets related to comfrey and cervical cancer were obtained (including ESR1, SRC, MMP9, PTGS2, etc.). And these genes were mainly enriched in 39 signaling pathways such as PI3K-Akt and estrogen. Molecular docking reminder that Lithospermum A has a higher affinity with ESR1, and Lithospermum B can form a stable conformation with SRC, MMP9, and PTGS2. Conclusion Lithospermum erythrorhizon is a potential drug candidate for the treatment of cervical cancer. It can treat cervical cancer through multi-component, multi-target, and multi-channel action.